MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

528.43 -0.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

522.64

Max

539.38

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+34.66% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1B 12B
Vorige openingsprijs	528.57
Vorige sluitingsprijs	528.43

Nieuwssentiment

By Acuity

50%

163 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 apr 2026, 22:56 UTC

Belangrijke Nieuwsgebeurtenissen

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisities, Fusies, Overnames

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Marktinformatie

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Winsten

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Winsten

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Marktinformatie

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Belangrijke Nieuwsgebeurtenissen

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Winsten

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisities, Fusies, Overnames

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Marktinformatie

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisities, Fusies, Overnames

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

34.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 704.88 USD 34.66%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

163 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.